Clinical Study Data Request Registered Users, Please Login

Find by:

Study ID:
Medicine:
Phase:

A Phase II, randomised, double-blind, active-controlled, dose-escalation study to determine the maximum well-tolerated starting dose of a new formulation of ropinirole in Parkinson's Disease patients not receiving other dopaminergic therapies
ropinirole
SKF-101468/166
Parkinson Disease
Phase 2
 
A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.
June 2014

Powered by ideaPoint, Inc.